Retinoids in hematology: a timely revival?
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
06 05 2021
06 05 2021
Historique:
received:
23
11
2020
accepted:
17
02
2021
pubmed:
3
3
2021
medline:
15
12
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
The retinoic acid receptors (RARA, RARB, and RARG) are ligand-regulated nuclear receptors that act as transcriptional switches. These master genes drew significant interest in the 1990s because of their key roles in embryogenesis and involvement in a rare malignancy, acute promyelocytic leukemia (APL), in which the RARA (and very rarely, RARG or RARB) genes are rearranged, underscoring the central role of deregulated retinoid signaling in leukemogenesis. Several recent provocative observations have revived interest in the roles of retinoids in non-APL acute myeloid leukemia (AML), as well as in normal hematopoietic differentiation. We review the role of retinoids in hematopoiesis, as well as in the treatment of non-APL AMLs. From this perspective, broader uses of retinoids in the management of hematopoietic tumors are discussed.
Identifiants
pubmed: 33651885
pii: S0006-4971(21)00510-3
doi: 10.1182/blood.2020010100
doi:
Substances chimiques
Receptors, Cytoplasmic and Nuclear
0
Retinoids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2429-2437Informations de copyright
© 2021 by The American Society of Hematology.